<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058482</url>
  </required_header>
  <id_info>
    <org_study_id>Nal01</org_study_id>
    <nct_id>NCT05058482</nct_id>
  </id_info>
  <brief_title>Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations</brief_title>
  <official_title>A Prospective, Multi-center, Randomized Parallel Controlled Study on the Safety and Effectiveness of the Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Hengruihongyuan Medical Technology Co. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Hengruihongyuan Medical Technology Co. LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is to verify the safety and effectiveness of the Non-adhesive Liquid&#xD;
      Embolic System(NALES) produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. in the&#xD;
      process of clinical use to support the application of the National Medical Products&#xD;
      Administration ( NMPA) product registration approval.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, randomized controlled trial was used in this study. Onyx Liquid&#xD;
      Embolic System and Marathon Flow Directed Micro Catheter, which were registered and marketed&#xD;
      in China and had good effect in the industry, were selected as the control devices. Subjects&#xD;
      requiring cerebral arteriovenous malformation embolization were selected to participate in&#xD;
      the trial based on pathological conditions and inclusion/exclusion criteria, and the use of&#xD;
      test products or control products was determined based on central randomized results. Imaging&#xD;
      data involving the main evaluation criteria were evaluated uniformly by the blind evaluators&#xD;
      of the leading unit, so as to reduce the bias caused by subjective factors of different&#xD;
      evaluators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 17, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective embolization rate of malformed masses</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Number of effective embolization subjects / Total number of subjects x 100%.Definition of effective embolization : Postoperative DSA angiographic malformation volume decreased ≥50%. Volume of malformed groups = length × width × height /2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRS score</measure>
    <time_frame>1,6,12months after surgery</time_frame>
    <description>MRS refers to the modified Rankin scale, which is used to measure the neurological recovery of patients after stroke. It has a scale of zero to six. The higher the score, the worse the neurological function. MRS scores were collected at 1, 6 and 12 months after the operation before discharge .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Success is represented by the ability to reach the lesion and embolize the malformed mass of the intended target, followed by successful catheter withdrawal from the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter performance evaluation</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>The ability of the catheter to reach the lesion .&#xD;
The catheter has broken at the tip and perforated.&#xD;
Intravascular complications associated with catheters occurred.&#xD;
Degree of difficulty in tube withdrawal&#xD;
Catheter jam</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of major adverse events related to device or surgical procedures within 1 month after surgery</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Major adverse events related to instrumentation or surgical procedures within 1 month after surgery: bleeding during embolization, catheter indwelling, bleeding after embolization, symptomatic cerebral infarction, and edema.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Intracranial Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>Non-adhesive Liquid Embolic System(NALES)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Onyx Liquid Embolic System&amp; Marathon Flow Directed Micro Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>embolism</intervention_name>
    <description>Cerebral arteriovenous malformation embolism</description>
    <arm_group_label>Non-adhesive Liquid Embolic System(NALES)</arm_group_label>
    <arm_group_label>Onyx Liquid Embolic System&amp; Marathon Flow Directed Micro Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years old, no gender limit.&#xD;
&#xD;
          2. The patient was diagnosed as cerebral arteriovenous malformation .&#xD;
&#xD;
          3. The patient had no history of bAVM treatment, including intervention, surgery or&#xD;
             radiotherapy .&#xD;
&#xD;
          4. Spetzler Martin, grade I-IV .&#xD;
&#xD;
          5. The patient voluntarily signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of heparin allergy.&#xD;
&#xD;
          2. The patient is allergic to contrast media.&#xD;
&#xD;
          3. Severe hepatic and renal insufficiency (serum creatinine ≥1.5 times the upper limit of&#xD;
             normal value, alanine aminotransferase ≥3 times the upper limit of normal value,&#xD;
             aspartate aminotransferase ≥3 times the upper limit of normal value).&#xD;
&#xD;
          4. Patient has irreversible coagulopathy (INR &gt; 1.5).&#xD;
&#xD;
          5. Intracranial hemorrhage 1 week before treatment.&#xD;
&#xD;
          6. MRS ≥4 due to neurological dysfunction.&#xD;
&#xD;
          7. Patients with planned malformation resection after embolization.&#xD;
&#xD;
          8. Blood flow related aneurysms of supplying artery that need to be treated by other&#xD;
             methods.&#xD;
&#xD;
          9. Complicated with severe cerebral artery stenosis.&#xD;
&#xD;
         10. Brain tumors that require recent surgery.&#xD;
&#xD;
         11. Complicated with proliferative cerebrovascular disease.&#xD;
&#xD;
         12. Pregnant or lactating women.&#xD;
&#xD;
         13. Participants who have participated in other clinical trials within the last 3 months&#xD;
             and failed to reach the end point.&#xD;
&#xD;
         14. The number of embolism is expected to be greater than or equal to 4 times during the&#xD;
             study period (within 1 year).&#xD;
&#xD;
         15. Subjects deemed unsuitable for this study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Liu, Doctor</last_name>
    <phone>13901780638</phone>
    <email>liu118@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chuanzhi Duan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nan Fang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Songtao Qi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dong Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huaizhang Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianxiao Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jincao Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ya Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjng Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunhua Hang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Eastern Theater Command</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>HanDong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xingen Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuxiang Gu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianmin Liu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>322000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianmin Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-adhesive Liquid Embolic System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

